fenofibric acid has been researched along with gw 501516 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beneton, V; Boullay, AB; Boyer, T; Brewster, AG; Donche, F; Forest, MC; Fouchet, MH; Gellibert, FJ; Grillot, DA; Lambert, MH; Laroze, A; Le Grumelec, C; Linget, JM; Montana, VG; Nguyen, VL; Nicodème, E; Patel, V; Penfornis, A; Pianetti, PM; Pineau, O; Pohin, D; Potvain, F; Poulain, G; Ruault, CB; Saunders, M; Sierra, ML; Toum, J; Xu, HE; Xu, RX | 1 |
| Daugaard, JR; Fleckner, J; Galsgaard, ED; Havranek, M; Jeppesen, CB; Jeppesen, L; Mogensen, JP; Olsen, GS; Panajotova, V; Pettersson, I; Pihera, P; Polivka, Z; Sauerberg, P; Wulff, EM; Ynddal, L | 1 |
| Dodo, K; Hashimoto, Y; Makishima, M; Sato, A; Sodeoka, M | 1 |
| Chew, GT; Sahebkar, A; Watts, GF | 1 |
1 review(s) available for fenofibric acid and gw 501516
| Article | Year |
|---|---|
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides | 2014 |
3 other study(ies) available for fenofibric acid and gw 501516
| Article | Year |
|---|---|
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dyslipidemias; Humans; Ligands; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Molecular; PPAR alpha; Propionates; Protein Structure, Tertiary; Rats; Rats, Wistar; Structure-Activity Relationship; Thiazoles; Triglycerides | 2007 |
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
Topics: Administration, Oral; Allyl Compounds; Animals; Apolipoprotein B-100; Binding Sites; Cell Line; Cholesterol Ester Transfer Proteins; Crystallography, X-Ray; Dietary Fats; Fatty Acids, Nonesterified; Female; Humans; Lipid Metabolism; Male; Mice; Mice, Transgenic; Models, Molecular; Muscle, Skeletal; Oxidation-Reduction; Phenylacetates; PPAR delta; Rats; Structure-Activity Relationship; Transcriptional Activation | 2007 |
Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists.
Topics: Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Conformation; PPAR alpha; PPAR gamma; Prostaglandins; Structure-Activity Relationship | 2013 |